DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Apabetalone is an investigational drug.
There have been 7 clinical trials for Apabetalone. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2015.
The most common disease conditions in clinical trials are Coronary Disease, Coronary Artery Disease, and Cardiovascular Diseases. The leading clinical trial sponsors are Resverlogix Corp, Steeve Provencher, and PPD.
There are eighty-eight US patents protecting this investigational drug and six hundred and eighty-eight international patents.
Recent Clinical Trials for Apabetalone
|An Open-Label Study of Apabetalone in Covid Infection||Resverlogix Corp||Phase 2/Phase 3|
|Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study||Steeve Provencher||Early Phase 1|
|Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease||Resverlogix Corp||Phase 1/Phase 2|
Top disease conditions for Apabetalone
Top clinical trial sponsors for Apabetalone
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Apabetalone||Get Started Free||Pharmaceutical compositions for substituted quinazolinones||Resverlogix Corp. (Calgary, Alberta, CA)||Get Started Free|
|Apabetalone||Get Started Free||Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug||The Regents of the University of California (Oakland, CA)||Get Started Free|
|Apabetalone||Get Started Free||Compositions containing HC-HA/PTX3 complexes and methods of use thereof||TISSUETECH, INC. (Miami, FL)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Apabetalone||Australia||AU2012330885||2031-11-01||Get Started Free|
|Apabetalone||Canada||CA2851996||2031-11-01||Get Started Free|
|Apabetalone||China||CN103945848||2031-11-01||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|